EN DE
STOCK COMPARISON

Alteogen vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Alteogen (196170) and Vertex Pharmaceuticals (VRTX) compare, as of Sep 5, 2026.

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Alteogen trades at KRW 288,500 versus a fair value of KRW 39,476 (-86%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).
Alteogen
196170.KQ · KRW · Health Care
-86%
upside to fair value
overvalued
PriceKRW 288,500
Fair ValueKRW 39,476
Quality70/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-50%
upside to fair value
overvalued
Price$558
Fair Value$279
Quality79/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

AlteogenVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
0.05×P/S (TTM)10.06×
—P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
−86.3%Fair value upside−50.0%
0.1%Dividend yield0.1%
KRW 371Dividend per share—
Profitability
55%Operating margin38%
165.00×EBIT margin trend (5Y)0.86×
25%Return on equity24%
8%Return on assets12%
Growth
-15%Revenue growth (YoY)8%
95.7%Avg. growth/yr (3Y)10.6%
38.5%Avg. growth/yr (5Y)14.2%
+79.7%Value creation/yr+13.6%
Balance & size
9.7×Interest coverage (EBIT/interest)357.9×
0.01×Debt / equity0.03×
$10BMarket cap$123B
healthyGrowth qualityhealthy

Alteogen leads: 7 to 3 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Alteogenof which business quality 71 · market factors 15 Vertex Pharmaceuticalsof which business quality 77 · market factors 79
ProfitabilityMargins and returns on capital today
71
72
Quality GrowthAre margins and returns improving?
95
65
CashflowEarnings quality: real cash, not paper profit
72
79
Fin. StrengthBalance sheet, leverage, solvency risk
86
92
InvestmentDisciplined investing over empire-building
8
58
Low VolatilityCalm price path (market factor)
33
85
MomentumPrice trend over the last 3–12 months (market factor)
9
70
52W MomentumDistance to the 52-week high (market factor)
6
89
Net IssuanceBuybacks instead of dilution
74
82

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyAlteogenPrice KRW 288,500Vertex PharmaceuticalsPrice $558
DCF Models-81%below the priceKRW 54,926-19%below the price$453
Earnings-Based-68%below the priceKRW 92,661-8%close to the price$516
Dividend Discountn/a-99%below the price$7.07
Multiples-89%below the priceKRW 32,849-50%below the price$278
Asset-Based-98%below the priceKRW 5,574-91%below the price$49.27
Growth DCF-85%below the priceKRW 44,371-38%below the price$348
Economic Profit-87%below the priceKRW 36,157-54%below the price$254
Growth Earnings-57%below the priceKRW 123,001+24%above the price$692
Minimum-98%below the priceKRW 5,574-99%below the price$7.07
Maximum-57%below the priceKRW 123,001+24%above the price$692
Median-85%below the priceKRW 44,371-44%below the price$313
Geometric mean-86%below the priceKRW 40,665-67%below the price$185

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Alteogen: 24 of 24 models see the stock below the current price.

Vertex Pharmaceuticals: 22 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Alteogen
Bear KRW 24,681Fair Value KRW 39,476Bull KRW 51,158
KRW 288,500 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$558 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Alteogen · Health Care

Quality score70 · Top 25%
Fair value upside-86% · bottom 25%

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-50% · below median

Bottom line

As of Sep 5, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Alteogen trades at KRW 288,500 versus a fair value of KRW 39,476 (-86%), while Vertex Pharmaceuticals trades at $558 versus $279 (-50%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →
Alteogen · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Alteogen

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupMerck & Company vs UnitedHealth Group

Related to Vertex Pharmaceuticals

AstraZeneca vs UnitedHealth GroupThermo Fisher Scientific vs UnitedHealth GroupAmgen vs UnitedHealth GroupAbbott Laboratories vs UnitedHealth Group
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.